| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 5817- | CBD, | COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells |
| - | vitro+vivo, | Lung, | A549 |
| 5818- | CBD, | Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress |
| - | in-vivo, | PC, | PANC1 |
| 5979- | CDT, | AgNPs, | Multifunctional nanomedicines-enabled chemodynamic-synergized multimodal tumor therapy via Fenton and Fenton-like reactions |
| - | Review, | Var, | NA |
| 5966- | CEL, | Determine whether administering celecoxib during radiotherapy can reduce the risk of recurrence of triple-negative breast cancer. Pilot study |
| - | Trial, | BC, | NA |
| 5960- | CEL, | Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers |
| - | Trial, | Pca, | NA |
| 5953- | Cela, | CUR, | The Combination of Celastrol and Curcumin Enhances the Antitumor Effect in Nasopharyngeal Carcinoma by Inducing Ferroptosis |
| - | vitro+vivo, | NPC, | NA |
| 5941- | Cela, | Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | OVCAR-3 |
| 5942- | Cela, | Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | H460 | - | in-vitro, | NSCLC, | PC9 |
| 5943- | Cela, | Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases |
| - | Review, | Arthritis, | NA | - | Review, | IBD, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 5948- | Cela, | Recent Trends in anti-tumor mechanisms and molecular targets of celastrol |
| - | Review, | Var, | NA |
| 5949- | Cela, | Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor |
| - | in-vitro, | BC, | MCF7 |
| 6635- | Cen, | Pharmacokinetics and metabolomics investigation of an orally modified formula of standardized Centella asiatica extract in healthy volunteers |
| - | Trial, | Nor, | NA |
| 6656- | Cen, | Recent insights into therapeutic potential and nanostructured carrier systems of Centella asiatica: An evidence-based review |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6649- | Cen, | Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action |
| - | in-vivo, | AD, | NA |
| 6646- | Cen, | Effectiveness of Gotu Kola Extract 750 mg and 1000 mg Compared with Folic Acid 3 mg in Improving Vascular Cognitive Impairment after Stroke |
| - | Trial, | Stroke, | NA |
| 5968- | CET, | Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer |
| - | in-vitro, | CRC, | NA |
| 5967- | CET, | FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer |
| - | Study, | CRC, | NA |
| 6020- | CGA, | BetaL, | Chlorogenic Acid Enhances Beta‐Lapachone‐Induced Cell Death by Suppressing Autophagy in NQO1‐Positive Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6019- | CGA, | immuno, | Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects |
| - | in-vivo, | Melanoma, | NA |
| 6018- | CGA, | Chlorogenic acid: a review on its mechanisms of anti-inflammation, disease treatment, and related delivery systems |
| - | Review, | Var, | NA | - | Review, | RCC, | NA |
| 6017- | CGA, | Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment |
| - | Review, | Var, | NA |
| 6016- | CGA, | Coffee Chlorogenic Acids Incorporation for Bioactivity Enhancement of Foods: A Review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Diabetic, | NA |
| 6008- | CGA, | Risk Assessment of Chlorogenic and Isochlorogenic Acids in Coffee By-Products |
| - | Review, | Nor, | NA |
| 6037- | CGA, | Pharmacokinetics and brain penetration study of chlorogenic acid in rats |
| - | in-vivo, | AD, | NA | - | in-vivo, | Stroke, | NA |
| 6036- | CGA, | Effect of Chlorogenic Acids on Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Trial |
| - | Trial, | Nor, | NA |
| 6034- | CGA, | Effect and mechanism of chlorogenic acid on cognitive dysfunction in mice by lipopolysaccharide-induced neuroinflammation |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 6630- | CGA, | In Vitro and In Silico Study on the Impact of Chlorogenic Acid in Colorectal Cancer Cells: Proliferation, Apoptosis, and Interaction with β-Catenin and LRP6 |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW480 |
| 1244- | CGA, | immuno, | Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody |
| - | in-vivo, | NA, | NA |
| 7184- | CHA, | Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance |
| - | in-vitro, | CML, | NA |
| 7168- | CHA, | The anticancer effect of chaetocin is enhanced by inhibition of autophagy |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | Liver, | HepG3 | - | in-vitro, | Liver, | HUH7 |
| 7166- | CHA, | Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1 |
| - | vitro+vivo, | AML, | U937 |
| 7165- | CHA, | The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase |
| - | in-vitro, | Cerv, | HeLa |
| 7164- | CHA, | Chaetocin induces apoptosis in human melanoma cells through the generation of reactive oxygen species and the intrinsic mitochondrial pathway, and exerts its anti-tumor activity in vivo |
| - | vitro+vivo, | Melanoma, | A375 |
| 7163- | CHA, | The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | OS, | U2OS | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HeLa | - | in-vivo, | Ovarian, | SKOV3 |
| 7160- | CHA, | Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress |
| - | in-vitro, | Lung, | A549 |
| 7159- | CHA, | ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin |
| - | vitro+vivo, | GC, | HGC27 | - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | BGC-823 | - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | Nor, | HEK293 |
| 2175- | Chemo, | VitB12, | FA, | Systemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients |
| - | Study, | BC, | NA |
| 6000- | Chit, | Chitosan in Modern Pharmacotherapy: From Drug Encapsulation to Targeted Delivery Systems |
| - | Review, | Var, | NA |
| 6001- | Chit, | Recent advances in engineering chitosan-based nanoplatforms in biotherapeutic multi-delivery for multi-targeted disease treatments: Promises and outlooks |
| - | Review, | Var, | HepG2 | - | Review, | AD, | NA |
| 5981- | Chit, | Chitosan-Based Drug Delivery Systems for Targeted Chemotherapy in Colorectal Cancer: A Scoping Review |
| - | Review, | CRC, | NA |
| 5984- | Chit, | Chitosan in cancer therapy: a dual role as a therapeutic agent and drug delivery system |
| - | Review, | Var, | NA |
| 5985- | Chit, | immuno, | Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies. |
| - | Review, | Var, | NA |
| 5987- | Chit, | Chitin, Chitosan, and Glycated Chitosan Regulate Immune Responses: The Novel Adjuvants for Cancer Vaccine |
| - | Review, | Var, | NA |
| 5991- | Chit, | Chitosan-Based Nanoencapsulated Essential Oils: Potential Leads against Breast Cancer Cells in Preclinical Studies |
| - | Review, | BC, | NA |
| 5999- | Chit, | How chitosan can help against breast cancer |
| - | Review, | BC, | NA |
| 5997- | Chit, | Using immunoadjuvant agent glycated chitosan to enhance anti-cancer stem like cell immunity induced by HIFU |
| - | in-vivo, | Lung, | NA |
| 5995- | Chit, | CUR, | Enhancement of anticancer activity and drug delivery of chitosan-curcumin nanoparticle via molecular docking and simulation analysis |
| - | vitro+vivo, | Var, | NA |
| 5994- | Chit, | Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action |
| - | Review, | Var, | NA |
| 5992- | Chit, | Preparation of chitosan nanoparticles for simultaneous drug delivery of dacarbazine and enoxaparin in melanoma |
| - | in-vitro, | Melanoma, | B16-F10 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid